Roche (OTCQX:RHHBY) (OTCQX:RHHBF) will finalize the acquisition of Poseida Therapeutics (NASDAQ:PSTX), a biopharmaceutical company specializing in complex immune cell therapies to treat several types of blood cancer, for up to $1.5 billion.

The agreement includes a cash payment of $9 per share, with an additional